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Abstract Frontotemporal lobar degeneration (FTLD) is a
heterogeneous group of disorders characterized by distur-
bances of behavior and personality and different types of
language impairment with or without concomitant features
of motor neuron disease or parkinsonism. FTLD is charac-
terized by atrophy of the frontal and anterior temporal brain
lobes. Detailed neuropathological studies have elicited pro-
teinopathies defined by inclusions of hyperphosphorylated
microtubule-associated protein tau, TAR DNA-binding
protein TDP-43, fused-in-sarcoma or yet unidentified pro-
teins in affected brain regions. Rather than the type of
proteinopathy, the site of neurodegeneration correlates
relatively well with the clinical presentation of FTLD.
Molecular genetic studies identified five disease genes, of
which the gene encoding the tau protein (MAPT), the growth
factor precursor gene granulin (GRN), and C9orf72 with
unknown function are most frequently mutated. Rare muta-
tions were also identified in the genes encoding valosin-
containing protein (VCP) and charged multivesicular body
protein 2B (CHMP2B). These genes are good markers to
distinguish underlying neuropathological phenotypes. Due
to the complex landscape of FTLD diseases, combined
characterization of clinical, imaging, biological and genetic
biomarkers is essential to establish a detailed diagnosis.
Although major progress has been made in FTLD research in
recent years, further studies are needed to completely map
out and correlate the clinical, pathological and genetic
entities, and to understand the underlying disease mecha-
nisms. In this review, we summarize the current state of the
rapidly progressing field of genetic, neuropathological and
clinical research of this intriguing condition.
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Introduction
History and significance
Frontotemporal lobar degeneration (FTLD) is an ana-
tomopathological descriptive term referring to a disorder
characterized by the relatively selective atrophy of the
frontal and anterior temporal lobes of the brain. Apart from
this commonality, FTLD is a clinically, genetically and
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pathologically heterogeneous group of disorders. Because
disease onset occurs before the age of 65 years in 75–80 %
of the patients, FTLD is considered a presenile dementia
[110, 122]. In the age group between 45 and 65 years, the
prevalence of FTLD has been estimated between 10 and 30
per 100,000 [11, 136], but large-scale epidemiological
studies are lacking. FTLD is the second most common
form of early-onset dementia, after Alzheimer’s disease
(AD) [19].
FTLD has a markedly strong familial component:
30–50 % of the FTLD patients report at least one relative
with similar symptomatology, and in 10–23 %, the disease
segregates in the family with an autosomal dominant
inheritance pattern [56, 57]. Five disease genes have been
identified to cause FTLD. Further, FTLD is associated with
genes that typically cause a clinical picture of amyotrophic
lateral sclerosis (ALS), the most common type of motor
neuron disease (MND). Common genetic, clinical and
pathological characteristics between FTLD and ALS are
manifold. In this era of rapidly evolving insights into the
pathophysiology of this challenging group of diseases,
the present review aims to provide a timely picture of the
clinical, neuropathological and genetic findings in FTLD
and the correlations between them.
Clinical phenotypes of FTLD and related conditions
FTLD can manifest as two clinically recognized subtypes
based on the presenting and predominant features of either
behavioral and personality changes, or language distur-
bances. The behavioral variant of frontotemporal dementia
(bvFTD) is characterized by severe changes in behavior and
personality such as disinhibition, apathy, loss of empathy, or
stereotypic behavior, leading to a loss of social competence
[73, 109, 127, 151]. Executive functions are impaired, while
at least in the initial stages of the disease, memory and per-
ceptuospatial skills are well preserved. As the differential
diagnosis in patients with psychiatric disturbances or AD is
not always straightforward, the ‘International Behavioral
Variant FTD Criteria Consortium’ developed international
consensus criteria for bvFTD. According to these criteria,
subclassifications were made in possible bvFTD defined
by clinical criteria, probable bvFTD supported by neuro-
imaging data, and definite bvFTD confirmation by neuro-
pathological evidence or a pathogenic mutation [127].
bvFTD accounts for more than 50 % of the FTLD patients.
The onset of bvFTD is typically before the age of 65 years,
with an average onset age of 58 years [71, 73].
If the patient presents with language difficulties, a
diagnosis of primary progressive aphasia (PPA) is made.
PPA was originally further categorized into progressive
nonfluent aphasia (PNFA) and semantic dementia (SD)
[73]. However, the clinical picture of a number of PPA
patients did not fit either diagnosis, which led to the
description of the third variant, logopenic progressive
aphasia (LPA). The lack of clear definitions of the three
subtypes led in 2011 to new recommendations for the
subclassification of PPA into nonfluent/agrammatic variant
PPA (the former PNFA), semantic variant PPA (the former
SD) and the logopenic variant PPA (also known as LPA)
[59]. Nonfluent/agrammatic variant PPA or PNFA is
characterized by effortful speech and grammatical error-
making, with relatively preserved language comprehen-
sion. Apraxia of speech (AOS) or orofacial apraxia is
frequently accompanying the aphasia [73]. PNFA is the
second most prevalent presentation of FTLD, accounting
for a large 25 % [71]. Semantic variant PPA or SD presents
with impaired comprehension and conceptual knowledge
with concomitant development of anomia, while speech
production is spared [59, 109, 151]. SD presents in
20–25 % of the FTLD patients [71]. LPA is mostly asso-
ciated with a neuropathological diagnosis of AD [121] and
is not considered part of the FTLD group of disorders.
Based on the evidence supporting the diagnosis of PPA, the
label ‘‘possible’’ (clinical features), ‘‘probable’’ (clinical
findings in combination with neuro-imaging) and ‘‘defi-
nite’’ (after post-mortem examination or when a gene
mutation is known) are provided [59, 125].
Overlap between the clinical syndromes of bvFTD, PNFA
and SD can occur during the progression of the disease and
clinical distinction between them is often complicated in
advanced disease stages. The median survival from the
onset of symptoms is 6–11 years, independent of age at
onset or gender [63, 130]. While some studies show no
differences in survival rates among the clinical subtypes of
FTLD, other studies suggested shorter survival in bvFTD and
longest survival in SD [63, 71, 115, 130]. The gender distri-
butionofFTLDappears tovaryby theclinical syndrome,with
a male preponderance in the behavioral and personality
disorders and a female predominance in the language
disorders [71].
The comorbidity of ALS with behavior alterations,
cognitive impairment or dementia has been noticed since
the early 20th century [91, 119, 129]. FTLD may precede,
follow or coincide with the onset of motor symptoms [172].
In one of the largest studies on neuropsychological dis-
turbances in ALS, 47 % of the patients showed some
degree of dysfunction in frontal lobe tests, which was in
15 % sufficient for a diagnosis of FTLD [129]. Conversely,
motor neuron dysfunction has been described in 40 % of
the FTLD patients, and the diagnostic criteria for ALS
were met in 15 %, referred to as FTLD-ALS [18, 90].
FTLD-ALS patients have a poor prognosis with a mean
survival of 2–3 years from the onset of first symptoms [63,
73]. The reported heritability of FTLD-ALS is high:
approximately 50 % is considered familial [56, 132, 141].
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Apart from MND, other conditions are closely related to
FTLD, including progressive supranuclear palsy (PSP)
syndromes, corticobasal syndrome (CBS), FTD with par-
kinsonism (FTDP) and argyrophilic grain disease (AGD).
The most common clinical syndromes are PSP syndromes
with a prevalence of 3.1 per 100,000, followed by CBS
with a prevalence of less than 1 per 100,000 [41]. PSP was
originally described as a clinical syndrome characterized
by extrapyramidal symptoms and a progressive dementia.
Patients present with a symmetrical, akinetic rigid parkin-
sonism, severe postural instability and supranuclear
ophthalmoplegia. Most patients develop the disease at
middle or late age (75 ± 8 years) and death occurs on
average 7 years later [35]. In more recent years, the spec-
trum of PSP syndromes has been extended to not only
include classical PSP syndrome, termed the Richardson’s
type, but also PSP-parkinsonism, which presents as a more
asymmetrical disorder resembling Parkinson’s disease
[177] and the syndrome of pure akinesia characterized by
freezing of gait and speech dysfluencies as most prominent
features [34, 177]. CBS most frequently presents as a
combined clinical picture, consisting of a focal cortical
deficit (e.g. limb apraxia, aphasia, frontal lobe syndrome,
alien limb phenomenon, cortical sensory loss) and a pro-
gressive asymmetrical movement disorder (myoclonus,
dystonia, tremor). In a later stage of the disease, patients
often develop cognitive dysfunctions, sometimes in com-
bination with a frontotemporal behavioral syndrome. The
term FTDP-17 was defined in 1997 [47, 153], describing
13 families presenting with a clinical syndrome of auto-
somal dominant disinhibition, dementia, parkinsonism, and
amyotrophy and showing genetic linkage to chromosome
17. Nowadays, we are able to differentiate mutations in the
MAPT or to the GRN gene, both located on chromosome
17. The clinical picture resembles bvFTD, while cognitive
deficits include anterograde memory dysfunction in an
initial stage, later accompanied by progressive deteriora-
tion of visuospatial function, orientation and global
memory. Eventually, mutism occurs. Motor signs typically
include the development of symmetrical bradykinesia
without resting tremor, in combination with axial rigidity
and postural instability. There is poor or no effect of
levodopa therapy. Other motor symptoms include vertical
gaze palsy, dystonia, upper and lower motor dysfunction,
eye lid apraxia and dysphagia [35]. The onset age can
range from the early 20s to the late 70s, with an average of
50 years. The clinical early presentation of AGD is similar
to AD but disease progression is less aggressive, with
patients having a clinical picture resembling mild cognitive
impairment (MCI) for many years [35, 44]. AGD accounts
for approximately 5 % of the neurodegenerative dementia
cases, with an increasing prevalence with advancing age
[35, 44]. As FTLD is a distinctive clinical, genetic and
neuropathological entity, it should be noted that an FTD
phenotype can also be caused by underlying AD pathology
(i.e. frontal variant AD). Similarly, a clinical phenotype of
CBS can be caused by AD pathology [61].
Neuropathology of FTLD and cliniconeuropathological
correlations
The FTLD brain is by definition characterized by diverse
patterns of atrophy of frontal and anterior temporal lobes.
Different patterns of atrophy have been described and a
strong correlation with clinical phenotypes was found. A
relatively symmetrical atrophy of the frontal lobes, insula,
anterior cingulate and anterior temporal lobes is associated
with bvFTD. An asymmetric atrophy of the left (linguistic
dominant) anterior inferior temporal lobe gives rise to SD.
Patients with an asymmetrical atrophy of the right anterior
temporal lobe (right-sided SD) present with a behavioral
syndrome similar to bvFTD. These patients develop emo-
tional bluntness and, in some cases, loss of interest and
bizarre affect. As the atrophy progresses, prosopagnosia
and associative agnosia are often seen in combination with
eating disorders and rigid, compulsive behavior. In patients
with PNFA, an asymmetric atrophy involving the anterior
perisylvian cortex, mainly of the dominant hemisphere, is
seen [59, 122].
On microscopic examination, the neuronal loss and
astrocytosis are seen in cortices of atrophied frontal and
temporal lobes. In addition, FTLD is a proteinopathy
characterized by the presence of abnormal, ubiquitinated
protein inclusions in cytoplasm or nuclei of neuronal
and glial cells. Adjunctive immunohistochemistry allows
subcategorization of these disorders into specific protein-
opathies based on the major constituent of the inclusions.
From a historic perspective, two pathological categories of
FTLD were initially made [20, 95, 103]: in a first group of
patients, the disease presented neurons and glial cells
containing inclusions of hyperphosphorylated tau protein,
therefore referred to as FTLD-tau [97], including Pick’s
disease (PiD). However, more than 50 % of the FTLD
patients presented with tau-negative ubiquitin staining
inclusions at the time of unknown composition, therefore
referred to as FTLD-Ubiquitin or FTLD-U [90, 95]. In
80–95 % [94, 131] of this group, inclusions were later
found to be composed of transactive response (TAR) DNA-
binding protein 43 (TDP-43) [111], thus referred to as
FTLD-TDP [95, 112]. A considerable number of TDP-
43-negative FTLD-U cases had inclusions of fused-
in-sarcoma protein (FUS), thus referred to as FTLD-FUS
[96]. However, in a small number of FTLD-U patients, the
inclusion protein remains unknown until today. This group
is referred to as FTLD-ubiquitin proteasome system
(FTLD-UPS) [36, 95].
Acta Neuropathol (2012) 124:353–372 355
123
Correlations were noted between the clinical FTLD
subtypes and underlying proteinopathies, but a strict one-
to-one relationship is lacking. An FTLD-FUS proteinopa-
thy is invariantly associated with a clinical diagnosis of
bvFTD, either with or without the signs of MND. However,
bvFTD is also associated with FTLD-tau and FTLD-TDP
(Fig. 1). Although PNFA and SD are both associated with
FTLD-tau and FTLD-TDP, PNFA is commonly associated
with tau pathology, especially when AOS or orofacial
apraxia is present. On the other hand, SD is, in most cases,
linked with TDP-43-immunoreactive pathology, although
tau pathology is sometimes observed. When SD is associ-
ated with FTLD-tau, patients often present with acalculia
[122]. In right-sided SD, the underlying neuropathology is
mostly a TDP-43 proteinopathy. Tau pathology was also
associated with FTD with parkinsonism, PSP syndromes,
CBS and AGD. Similarly, TDP-43 and FUS proteinopa-
thies are also commonly found in MND with or without
FTLD.
Molecular genetics
Positive family history is observed in 40–50 % of the
FTLD patients [85] and at least 10–50 % of the patients are
associated with an inheritance pattern compatible with a
highly penetrant Mendelian mutation [32, 107]. When
considering clinical FTLD subtypes, family history is most
prominent in bvFTD (45 %), especially when concomitant
symptoms of MND are present (60 %), while SD appeared
to be the least hereditary FTLD subtype (\20 %) [56].
Molecular genetic studies have identified five genes that,
when mutated, cause FTLD: C9orf72, granulin (GRN), the
microtubule associated protein tau gene (MAPT), the gene
encoding valosin-containing protein (VCP) and the charged
multivesicular body protein 2B (CHMP2B) [30]. Mutations
in common ALS genes TARDBP and FUS (see ALS review
in this issue), in rare cases, present clinically with FTLD
[8, 171], even without the observed signs of MND (e.g.
[68]). The relative mutation frequencies of these genes vary
substantially among different populations due to founder
effects resulting in a regionally high occurrence of one or a
limited number of specific mutations. Also, reported
mutation frequencies vary significantly between studies,
depending on the method of patient ascertainment (e.g.
population-based vs. hospital-based) and employed inclu-
sion criteria (e.g. clinical vs. pathological diagnosis,
familial vs. non-familial or both). However, in general
terms, mutations in C9orf72, GRN and MAPT are the most
common and together explain at least 17 % of the familial
FTLD (Table 2). In two genetically fully documented
FTLD series, summed C9orf72, GRN and MAPT mutation
frequencies were 32 [33] and 40 % [55]. Mutations in VCP
and CHMP2B are rare, each explaining less than 1 % of the
familial FTLD.
As the mutant gene is initiating the biological disease
processes underlying the neuropathological changes, a
relatively strict correlation between the affected gene and
associated neuropathology is observed (Fig. 1). However,
due to the lack of a tight correlation between the type
of pathology and the clinical manifestation thereof, the
Fig. 1 Diagram illustrating the
clinical, genetic and
neuropathological correlations
in FTLD. The gray background
of the genetics box represents
the genetically unexplained
fraction in FTLD cases overall
(as compared to familial cases
in Table 2)
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correlation between the disease gene and associated clini-
cal phenotype is limited.
In addition to the highly penetrant Mendelian FTLD
genes, few susceptibility genes are reported. From the
Mendelian genes, MAPT appears to also harbor a genetic
risk to develop tauopathies [6, 64]. The only systematic
genome-wide association study in FTLD reported until
today identified TMEM106B at chromosome 7p21 as a risk
factor for FTLD-TDP [165].
Autosomal dominant genes
MAPT
The first significant genetic linkage found in FTLD fami-
lies was with markers at chromosome 17q21 [69, 120,
154]. Linkage was described in 13 families in which a
consensus clinical syndrome of autosomal dominant dis-
inhibition, dementia, parkinsonism, and amyotrophy was
found, termed FTDP-17 [47]. As tau was implicated in
FTLD pathology and the chromosomal location of MAPT
coincided with the linkage at chromosome 17, MAPT was
the most obvious candidate gene and mutations were
identified in FTDP-17 families [69]. Today, 44 different
MAPT mutations are reported in 134 FTLD families [30]
(Table 2). The mutations are mainly clustered in the five
most 30 exons from 9 to 13, encoding the four microtubule-
binding domains of tau. In normal brain, the tau protein
occurs as six isoforms of which three contain three
microtubule-binding domains (3R tau) and three contain
four microtubule-binding domains (4R tau) [41]. A sub-
stantial number of mutations were located in the intron 10
splice donor site or intronic splice regulatory elements
resulting in aberrant splicing of exon 10. Interestingly,
MAPT exon 10 encodes one of the microtubule-binding
domains and the mutations affecting the splicing of this
exon result in aberrant ratios of 3R and 4R tau [38]. Syn-
onymous and nonsynonymous mutations in exon 10 were
shown to locate in exonic splice regulatory elements
resulting in similar aberrant splicing effects [39]. In addi-
tion, missense mutations are identified that affect the amino
acid sequence of the microtubule-binding domains. Muta-
tions affect the binding of tau to tubulin either due to an
increased expression of 4R tau relative to 3R tau isoforms,
or due to the altered binding properties of mutant tau
protein [123]. The mutations thus disturb the subtle equi-
librium between cytoskeletal assembly and disassembly
affecting neuronal plasticity and axonal transport across the
microtubules. In addition, coding MAPT mutations
increase the tendency of tau to form neurotoxic aggregates.
Mutations in exon 10 lead to 4R tau in both neurons and
glia, while mutations outside exon 10 lead to neuronal
accumulation of 3R tau and 4R tau [133]. Except for
p.P301L and IVS10?16C[T that occur in 32 and 27
families, respectively, MAPT mutations are rare and seen in
single families.
FTLD due to MAPT mutations is invariantly of the
pathological type FTLD-tau, including PiD. In PiD
pathology, the cardinal microscopic features are neuronal
intracytoplasmatic spheroid tau-containing Pick bodies in
the granular neurons of the dentate gyrus and in pyramidal
neurons of the hippocampus and affected neocortical
regions (Fig. 2a–c). Pick bodies, mainly localized in cor-
tical layers II and III, and to a lesser extent also in deeper
layers [41], specifically accumulate insoluble 3R tau [35,
41, 48, 73]. In addition to FTLD-tau, MAPT mutations
have also been associated with other tauopathies including
PSP, CBS, FTD with parkinsonism and the rarely seen
AGD [73, 79]. The typical tau lesions in PSP are globose
neurofibrillary tangles (NFT) found in neurons of the
subcortical nuclei [35, 41, 73]. In CBS patients, heteroge-
neous tau-immunoreactive inclusions are also found in
cortical neurons and neurons in substantia nigra and locus
coeruleus. Other characteristic hallmarks are astrocytic
plaques containing hyperphosphorylated tau and oligo-
dendroglial inclusions [35, 41]. The neuropathological
hallmark of FTD with parkinsonism is the combination of
tau-immunoreactive aggregates in neurons, astrocytes and
oligodendroglial cells, throughout cortex, deep gray and
subcortical white matter [35, 41]. Often, these lesions are
already extensive in early and intermediate stages of the
disease. In AGD, on external macroscopic examination,
mild diffuse cortical atrophy is seen, with a predilection of
the ambient gyrus [35, 44]. The histopathological hallmark
is the presence of argyrophilic grains (ArG). These ArG are
present throughout the neuropil of cortical and subcortical
structures. Lesions are initially present in the amygdala and
temporal allocortex, spreading toward temporal neocortex
as disease progresses.
FTLD-tau is mainly associated with bvFTD, however,
forms of PPA are also reported [105]. Symptoms of MND
are rare. On average, FTLD-tau is characterized by the
earliest onset age in the FTLD syndromes, although the
range of onset ages is large and strongly overlapping with
other types of FTLD. A literature survey of 228 FTLD
patients carrying a MAPT mutation demonstrated that the
average onset age was 48 ± 10 years with a disease
duration of 9 ± 5.5 years [27].
GRN
In some families linked to chromosome 17q21, extensive
mutation analyses could not identify a MAPT mutation. It
became apparent that, in FTLD families negative for
MAPT mutations, the characteristic pathological inclusions
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were of the tau-negative, ubiquitin-positive types suggest-
ing that mutations in another gene at the same genetic locus
were causing this FTLD-U type of disease. Extensive
mutation analyses of other positional candidate genes
identified mutation in the nearby GRN gene [7, 28]. To
date, 69 different GRN mutations have been reported in
231 families [30] (Table 2). GRN mutations are distributed
across the complete coding region and splice sites of the
gene. They are loss-of-function mutations leading to
reduced functional protein and resulting in haplo-insuffi-
ciency [52]. Most mutations produce null alleles as a result
of mRNA decay mediated by a nonsense or frameshift
mutation [7, 28, 50], but other mechanisms including gene
deletion [53] and defective protein sorting [143] are
described as well. GRN encodes progranulin, a ubiqui-
tously expressed growth factor precursor consisting of 7.5
granulin peptides [1]. Both full-length progranulin and the
granulin peptides are implicated in a wide range of bio-
logical processes such as inflammation and wound repair,
as well as in pathological conditions including tumori-
genesis [62]. Although their roles in the CNS are not well
established, in vitro and in vivo studies suggest a neuro-
trophic function involved in neuronal survival and neurite
outgrowth [2, 138, 164, 178].
The effect of GRN missense mutations on reduced
function and resulting phenotype is not straightforward:
some compromise protein stability or cellular sorting,
which might result in complete loss of function and lead to
haplo-insufficiency, thereby behaving as highly penetrant
FTLD mutations. Clear examples of loss-of-function
(LOF) missense mutations are those disrupting the signal
peptide [104, 143] or affecting the disulfide bonds control-
ling the characteristic granulin fold [166]. Other missense
mutations might only partially compromise function and
behave as risk alleles [29]. GRN missense mutations have
been implicated in AD risk [15, 150] and survival in ALS
[148]. A useful measure of the reduced GRN function,
discriminating between pathogenic and neutral missense
mutations, is the granulin protein level in cerebrospinal
fluid [22, 164], plasma [21, 45] and serum [149], although
the correlation between protein expression level and asso-
ciated disease risk is poorly studied.
All GRN-associated FTLD patients have a FTLD-TDP
proteinopathy [4, 117]. The presence of TDP-43 positive
inclusions is invariably associated with a decreased phys-
iologically normal nuclear staining [36, 95]. Recent
neuropathological studies elicited four FTLD-TDP sub-
types A to D based on the cortical distribution, intracellular
location and morphology of the inclusions [99] (Table 1;
Fig. 3). Based on the large clinicopathological studies, the
most common FTLD-TDP subtype is type A accounting for
41–49 % of the cases, followed by type B with 28–34 %
and type C with 17–25 %, while type D is rare [19, 73]. All
GRN mutations are associated with FTLD-TDP type A
(Fig. 3a–c), and in turn mutations in GRN explain about
40 % of these cases [133]. In FTLD-TDP type A, many
neuronal cytoplasmic inclusions (NCI), short dystrophic
neurites (DN) and some lentiform neuronal intranuclear
Fig. 2 FTLD-tau pathology in brain sections of a Pick disease patient
with bvFTD after immunostaining with AT8 antibody. a Frontal cortex
(F-cx), b temporal neocortex (T-cx), c hippocampus. Arrowheads
indicate the characteristic Pick bodies representing neuronal intracy-
toplasmatic spheroid tau inclusions
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inclusions (NII) are observed in layer II of the affected
neocortex. NCI in the dentate granular gyrus of the hip-
pocampus are variable in number [99].
Despite the fact that haplo-insufficiency is the common
disease mechanism in all patients carrying a GRN mutation,
the associated clinical phenotype is variable, including
bvFTD and PNFA [88, 125]. Parkinsonian symptoms are
often observed, but motor neuron symptoms are rare [23].
Sporadically, clinical diagnoses of related neurodegenera-
tive diseases including AD and parkinsonian disorders have
been associated with GRN mutations [14, 21, 22, 88]. A
literature survey of 183 patients with GRN-associated
FTLD demonstrated that the onset age was on average
61 ± 9 years and 13 years later than in MAPT mutation
carriers although as in FTLD-tau, onset ages are highly
variable, ranging from 35 to 87 years [29, 30]. A consid-
erable age-dependent penetrance was described with
50–60 % of the mutation carriers being affected by the age
of 60 years and 90–95 % by the age of 70 years [50, 125].
Consequently, family history is not always apparent and
GRN mutations are found in a significant number of FTLD
patients classified as being sporadic [87].
C9orf72
Genetic linkage [12, 54, 89, 93, 102, 162, 163] and asso-
ciation [83, 144, 170] studies in FTLD-TDP, FTLD-ALS
and ALS suggested a common genetic defect located at
chromosome 9p21 in the complete spectrum of diseases in
the FTLD–MND complex [55]. Extensive mutation anal-
yses of positional candidate genes identified an expanded
noncoding G4C2 hexanucleotide repeat in C9orf72
explaining linkage and association [33, 55, 128]. In the
normal population, the size of the G4C2 repeat ranges from
3 to 25 units, which is expanded to at least 60 units in
patients [33, 55, 128]. Accurate size estimations of the
expanded repeat in a substantial number of carriers are
lacking, as the commonly used detection method based on
the repeat-primed PCR does not differentiate repeat sizes
[60 units. In one study, Southern blot analyses of a limited
number of repeat expansion carriers estimated repeat sizes
between 700 and 1,600 units [33]. In an extended study,
pathological C9orf72 repeat expansions were observed in
11.4 % of the 1,381 FTLD patients of European origin,
rising to 24.8 % in familial patients [101]. The same study
reported a C9orf72 repeat expansion frequency of 6.0 % in
sporadic FTLD. Whether this high mutation frequency in
patients without family history of disease is explained by a
high de novo repeat expansion rate remains to be deter-
mined, but a preliminary study suggests that this is more
likely explained by incomplete penetrance [116].
C9orf72 encodes a ubiquitously expressed protein of
unknown function. It is expressed as three major transcripts
[33] and the expanded G4C2 repeat is located in the
proximal regulatory region of C9orf72 [55], upstream of
one and in the first intron of the two other transcripts.
Repeat expansion results in near complete loss of expres-
sion of the major gene transcripts [33, 55, 128]. In addition,
accumulation of transcripts harboring the expanded G4C2
repeat in nuclear RNA foci was described [33] although
this was not replicated in another study [146]. Whether
haplo-insufficiency due to the loss of transcription, RNA
toxicity due to sequestration of RNA-binding proteins in
RNA foci, and/or yet unidentified mechanisms are con-
tributing to disease, needs further investigation.
Before the identification of the C9orf72 repeat expansions,
FTLD linked to chromosome 9p21 was neuropathologically
characterized as being of the TDP-43 proteinopathy type B.
The pathological characteristics of FTLD-TDP type B
(Fig. 3d–f) include NCI throughout the entire cortical








Type A GRN, C9orf72 bvFTD (PNFA) Many NCI and DN in superficial cortical layers (layer II)
NII in superficial cortical layers GCI
Type B C9orf72 FTD-MND bvFTD NCI throughout the entire cortical thickness
NCI in hypoglossal nucleus and in ventral horn of the spinal cord
Pre-inclusions
Type C SD (bvFTD) Long DN in superficial cortical layers
Few NCI and NII
Type D VCP IBMPFD Many NII and DN throughout the entire cortical thickness
Few NCI
bvFTD behavioral variant frontotemporal dementia, PNFA primary nonfluent aphasia, FTD-MND frontotemporal dementia with motor neuron
disease, SD semantic dementia, IBMPFD inclusion body myopathy, Paget disease of bone and frontotemporal dementia, NCI neuronal cyto-
plasmic inclusions, NII neuronal intranuclear inclusions, GCI glial cytoplasmic inclusions, DN dystrophic neurites
a See Table 2 for full gene names
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thickness [99]. NCI are seen in the granular cells of the
dentate gyrus of the hippocampus. In some patients, NCI
can also be found in the motor neurons of the hypoglossal
nuclei and ventral horn of the spinal cord. Next to these
TDP-43 inclusions, granular ‘‘pre’’-inclusions are seen in
affected cortical regions [36]. Ubiquitin staining of these
pre-inclusions is negative. Furthermore, GCI are often seen
in brain stem and spinal cord [36]. When the pathological
C9orf72 repeat expansion was identified, a larger number
patients with neuropathological documentation could be
attributed to this mutation, revealing a wider pathological
diversity. In a substantial number of patients, the number
and distribution of TDP-43 inclusions were more consis-
tent with a TDP-43 type A proteinopathy [107] or
intermediate to type B and type A proteinopathy [152].
Alternatively, the TDP-43 lesion load could be relatively
limited or even absent resulting in a pathological diagnosis
of FTLD-UPS in rare patients [55, 107]. Abundant p62
positive, TDP-43 negative NCI and rare NII were seen in
the pyramidal cell layer of the hippocampus and cerebellar
granular layer of most patients [3, 13]. Remarkably, sim-
ilar brain inclusions were also observed in ALS patients
without associated cognitive decline [158]. Interestingly,
the sequestosome 1 gene (SQSTM1) encoding the p62
protein harbors mutations leading to ALS [42] and Paget
disease of bone (PDB) [58]. Nevertheless, p62 immuno-
reactivity of the TDP-43-negative NCI might indicate
general staining of proteins of the ubiquitin–proteasome
system (UPS) for protein degradation, and the hallmark
protein of these aggregations remains to be identified. The
presence of DN and aggregates that were immunoreactive
to ubiquilin (UBQLN) in the molecular layer of the hip-
pocampus and throughout the neocortex was shown to be
highly specific for the C9orf72 mutation. Further, UBQLN
and p62 colocalized in NCI in the dentate gyrus of the
hippocampus and the granular layer of the cerebellum [13].
Staining of C9orf72 itself has until today remained
inconclusive. Polyclonal antibodies against both protein
isoforms showed a punctiform staining of synaptic termi-
nals in the CA4 region of the hippocampus in patients with
the C9orf72 mutation, but also in patients with AD and
controls [13, 33, 146].
C9orf72 repeat expansions clinically present with a
widely variable phenotype including FTLD, ALS or
FTLD-ALS [33, 55, 128]. With a mutation frequency of
30 % in FTLD-ALS [55], it is the only known common
disease gene in this condition. Independent of concomitant
ALS, FTLD is mostly of the behavioral type but patients
with PPA have been described [33, 55, 146, 152]. Reported
mean onset ages ranged between 55.3 and 58.3 years [33,
55, 146, 152] and are intermediate to onset ages in FTLD
associated with MAPT and GRN. Also here, a high vari-
ability in onset age was noted, even among patients of the
same family [33, 55]. Typical of repeat expansion diseases,
genetic anticipation has been suggested with decreasing
onset ages in younger generations [5, 24, 43, 156], and a
decrease in onset age of 7 years in the younger of two
subsequent generations has been suggested for ALS [24].
However, reports correlating sizes of the expanded repeat
allele and onset age are lacking.
VCP
VCP mutations were identified by linkage analysis studies in
autosomal dominant families with disabling muscle weak-
ness due to inclusion body myopathy (IBM), osteolytic bone
lesions consistent with PDB and FTLD (IBMPFD) [174].
Today, 17 different mutations have been identified in 41
independent families [30]. Incomplete penetrance was noted
for all three clinical characteristic features and patients may
present with classical FTLD.
VCP encodes a ubiquitously expressed member of a
family of ATPases associated with a wide range of cellular
functions through interactions with different adaptor pro-
teins [175]. All IBMPFD mutations reside at the interface
between the D1 ATPase and the N-domain of the CDC48-
like protein [175]. The best supported hypotheses of the
disease mechanism of VCP mutations are disturbed ubiq-
uitin–proteasome mediated protein degradation [31],
autophagy [74], or both [75]. FTLD patients with a VCP
mutation are associated with TDP-43 proteinopathy type D
[176] characterized by large numbers of NCI, NII and DN
in affected neocortical regions [99] (Fig. 3g–i). Some
inclusions also stain for VCP protein p97 [140].
Symptoms of FTLD due to a VCP mutation become
apparent in the mid-50s in 25–30 % of the IBMPFD
patients [76, 78, 174]. The incomplete penetrance of the
three clinical characteristics IBM, PDB and FTLD is
independent of the underlying mutation [76, 78, 108, 174].
However, in FTLD, VCP mutations are rare and represent
less than 1 % of the familial FTLD (Table 2). The most
Fig. 3 Different types of TDP-43 pathology in brains of patients with
GRN mutation, C9orf72 hexanucleotide repeat expansion and VCP
mutation after immunostaining with TDP-43 antibody. a–c TDP-43
type A pathology in a bvFTD patient of family DR8, carrying the
GRN IVS0 ? 5G[C mutation [14, 28]. Arrowhead, double arrow-
head and arrow show moderate NCI, DN and NII load, respectively,
in layer II of temporal (a) and frontal (b) neocortex. c Higher
magnification of NCI load in frontal cortex. d–f TDP-43 type B
pathology in a bvFTD patient with the C9orf72 hexanucleotide repeat
expansion [55]. Arrowhead and arrow show NCI and DN, respec-
tively, spread throughout the entire cortical thickness in frontal cortex
(d), temporal neocortex (e) and NCI in neostriatum (f, higher
magnification). g–i TDP-43 type D pathology in a bvFTD patient
carrying the VCP p.Arg159His mutation [168]. Note the extensive
NCI (arrowhead), NII (double arrowhead) and DN (arrow) in frontal
cortex (g), temporal neocortex (h, i, higher magnification)
b
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frequently reported FTLD subtypes are bvFTD and SD
[176]. Interestingly, a single study reported VCP mutations
in 1–2 % of the ALS patients in the absence of dementia
symptoms [72, 77].
CHMP2B
Linkage analyses in a large Danish FTLD family identified a
mutation in CHMP2B at chromosome 3p11.2 [147].
CHMP2B encodes a component of the heteromeric ESCRT-III
complex with functions in the endosomal–lysosomal and
the autophagic protein degradation pathway. The gene is
expressed in neurons of all major brain regions. Mutations
affect the C-terminal end of the protein due to aberrant
splicing.
CHMP2B mutations were associated with enlarged
vacuoles in cortical neurons in the frontal, temporal, pari-
etal and occipital cortices, due to impaired endosome–
lysosome fusion [160], and impairment of autophagy [25].
Ubiquitin-immunoreactive NCI do not stain for tau, TDP-
43 or FUS antibodies [65, 66], consistent with a patho-
logical classification of FTLD-UPS [100].
The general clinical diagnoses in patients of the large
Danish family corresponded to bvFTD, with early per-
sonality changes being the most common feature [60]. In
other patients, progressive aphasia involvement was
described, although no diagnosis of PNFA, SD or LPA
could be made. The aphasia is characterized by a reduction
in spontaneous speech sometimes leading to mutism and
preserved reading and repetition, most consistent with a
dynamic aphasia [70, 167]. The average onset age is
58 years, ranging between 46 and 65 years [60, 70]. The
CHMP2B p.Gln206His mutation was reported in two ALS
patients [25, 117]. Other missense mutations have been
described in patients with FTLD and/or MND; however,
their pathogenic nature remains unclear [30].
TARDBP and FUS
Mutations in the genes encoding the TDP-43 (TARDBP)
and fused-in-sarcoma (FUS) proteins are typically associ-
ated with ALS. TARDBP mutations were initially identified
[155] as a direct consequence of the identification of TDP-
43-derived protein species as the major constituent of the
aggregates found in upper and lower motor neurons of ALS
patients without SOD1 mutations and in FTLD-U [4, 117].
Whereas 5 % of the familial ALS patients have a TARDBP
mutation, mutations are rarely found in FTLD and FTD-
MND [8, 10].
TDP-43 is an RNA-binding protein that forms hetero-
geneous nuclear ribonucleoprotein complexes (hnRNP)
which function in RNA processing activities of several
cellular functions, including transcription, RNA splicing
and microRNA processing [16, 17, 118]. Missense muta-
tions were found in the C-terminal glycine-rich region
involved in protein–protein interactions [118]. Similar to
TARDBP, FUS is a member of the hnRNP family. Its
location at chromosome 16p11.2, made it an excellent
candidate gene to explain previously established genetic
linkage to the same chromosomal region in multiple ALS
families [137, 139] and mutation analyses of patients in
these and other families identified FUS mutations [80].
Although FUS represents an ALS gene, a mutational
analysis of the FUS gene in 122 patients with FTLD
revealed one novel p.Met254Val mutation in a patient with
pure bvFTD. The silico analysis of this missense mutation
predicted a pathogenic affect; however, the biologic rele-
vance of this mutation remains elusive [157, 171].
Interestingly, an accumulation of FUS protein in inclusion
bodies in neuronal cytoplasm and nucleus was associated
with three clinicopathological subtypes of FTLD, defined by
specific characteristics and location of NCI and NII [92,
97, 98, 114]. The first type is pathologically characterized
by severe atrophy of the caudate nucleus and the fronto-
temporal cortex. Compact, round to oval kidney-shaped
NCI and vermiform NII are localized in neocortex,
granule cells of the dentate gyrus, striatum and to a lesser
extent in globus pallidus, thalamus and periaqueductal
gray matter (Fig. 4a–c). The cerebellar cortex is never
affected. NCI and NII are not detected upon hematoxylin–
eosin staining and were not immunoreactive to interme-
diate neurofilament on IHC. This type of FUS pathology
is associated with a severe clinical syndrome resembling
bvFTD and is referred to as atypical FTLD-U (aFTLD-U)
[94]. Onset of disease is early, in 30s or 40s, and disease
duration is approximately 7 years [85]. aFTLD-U is the
most frequent FTLD-FUS subtype, accounting for 7–20 %
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of FTLD-U cases [94, 131, 142, 161]. The second FTLD-
FUS type is characterized by an asymmetric atrophy of
frontotemporal cortex and neostriatum, which is less
severe than in aFTLD-U [85]. NCI and NII stain with
FUS antibodies and to a lesser extent with antibodies
against type IV interfilaments, alpha-internexin and neu-
rofilaments. Therefore, this FTLD-FUS type is referred
to as neuronal intermediate filament inclusion disease
(NIFID) [94, 113]. Clinically NIFID patients usually
develop a rapidly evolving FTD syndrome, mostly bvFTD,
in combination with motor disorders such as parkinsonian
or motor neuron symptoms. Patients usually develop the
disease between 40 and 60 years of age, but earlier onset
has been described and disease duration is on average
approximately 3 years [85]. Considerable neuropathologi-
cal similarities exist between aFTLD-U and NIFID;
however, distinctive differences are observed. In NIFID,
FUS-immunoreactive NCI are more extensive and wide-
spread and are particularly numerous in CA1 and
subiculum, but not in the granular layer of the dentate
gyrus. The NCI morphology in NIFID patients is very
heterogeneous, varying from small round to oval or
tangle-like and annular shapes [73, 98, 100]. While less
FUS-immunoreactive inclusions are seen in aFTLD-U,
microscopic evaluation of aFTLD-U patients often shows
sclerosis of the hippocampus and subcortical structures, for
example, caudate nucleus, putamen and substantia nigra
[85]. Another difference could be the presence of the NII,
which are variably found in the hippocampus, but rare in
other brain regions of NIFID patients, and are far more
numerous in aFTLD-U patients [98, 100]. In the third
FTLD-FUS type, referred to as basophilic inclusion body
disease (BIBD), basophilic NCI staining with hematoxylin
and eosin are seen in the pontine nuclei and to a lesser
extent also in cerebral cortex [73, 98, 100, 106]. The
basophilic NCI show FUS immunoreactivity in frontal
cortex, basal ganglia and brain stem [98, 100]. BIBD pre-
sents with a clinical syndrome of early-onset ALS,
occasionally accompanied with bvFTD.
Susceptibility genes and risk loci
Compared with other complex neurodegenerative brain
diseases including AD, little is known about susceptibility
genes contributing to the risk of developing FTLD. This is
mainly due to the fact that the familial component in FTLD
is higher, and most research efforts aimed at the identifi-
cation of Mendelian gene mutations. Also, the clinical and
neuropathological heterogeneity of FTLD diseases have
hampered large-scale genetic association studies in homo-
geneous patient series. One exception is the genome-wide
association study in FTLD-TDP which has resulted in the
identification of TMEM106B at chromosome 7p21 [165].
Nevertheless, other susceptibility genes are to be expected
especially in the SD type of FTLD, in which family history
is much less pronounced than in bvFTD and PNFA [32].
Consistent with this observation, mutations in the known
Fig. 4 aFTLD-U patient with FUS pathology without any known mutation after immunostaining with FUS antibody. The arrowhead shows the
kidney-shaped NCI in affected neostriatum (a) and frontal cortex (b, c, higher magnification)
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FTLD genes were not associated with SD apart from a few
atypical cases. Interestingly, SD is associated with a dis-
tinct type C of TDP-43 pathology suggesting a distinct
disease mechanism [73]. FTLD-TDP type C is character-
ized by the presence of long DN localized in the superficial
cortical layers, mainly layer II. NCI and NII are rare or
absent compared to the other subtypes. Glial pathology is
rare [99]. Together, these observations might suggest that
SD is clinically, pathologically and genetically distinct
from other types of FTLD and might predominantly be
caused by the interaction of multiple yet unknown sus-
ceptibility genes.
TMEM106B was the only gene located in a single
linkage disequilibrium block at 7p21 in which multiple
single nucleotide polymorphisms (SNPs) were significantly
associated in a series of 515 FTLD-TDP patients, a finding
that was replicated in a second series of 89 FTLD-TDP
patients [165]. In subsequent studies, association could be
confirmed in one patient series [169], but not in another
series [135]. It was found that TMEM106B may also con-
tribute to the risk of developing FTLD in carriers of GRN
mutations [165] possibly by modulating the levels of GRN
secretion [26], however, other studies were not consistent
with these findings [84, 169]. Interestingly, TMEM106B
may also be associated with cognitive impairment in ALS
[173].
TMEM106B is a type 2 integral membrane protein with
unknown function, localizing to late endosomes and lyso-
somes [84]. The chromosome 7p21 risk haplotype was
reported to act through altered TMEM106B gene expres-
sion in brain [165], although this was not confirmed in
another study [169]. Interestingly, increased levels of
TMEM106B were also associated with the inhibition of
vacuolar H?-ATPases, a finding which may provide an
unexpected biochemical link to GRN, since this protein
is also strongly increased by the inhibition of vacuolar
H?-ATPases [84].
Apart from the systematic genome-wide association
study in FTLD-TDP [165], candidate gene association
studies have reported genetic association of FTLD with
other genes. In a series of pathologically confirmed FTLD-
U patients without GRN mutations, a common genetic
variant located in the 30-untranslated region (UTR) of GRN
in a binding site for miR-659 was identified as a major
susceptibility factor for FTLD-U [126]. A significant
reduction of GRN protein was observed in homozygous
T-allele carriers in vivo, suggesting a similar mode of
action as heterozygous loss-of-function mutations in GRN
[126]. Another variant in the first intron of GRN, poten-
tially affecting its expression, was also reported to be
associated with FTLD in another patient series [49]. Nev-
ertheless, other studies could not confirm the genetic risk
for FTLD associated with variants in GRN [134, 152].
Besides harboring Mendelian FTLD mutations, MAPT
was associated with risk of PSP [6, 64, 67], CBS [37, 67] and
PD [40, 159], but inconsistent results were found in FTLD
[9, 51, 86]. MAPT is represented in the human population as
two genetically distinct haplotypes H1 and H2 due to its
genomic location inside an inversion polymorphism [27].
The H1 haplotype is consistently overrepresented in 4R tau
disorders, PSP and CBD [6, 67]. In young PSP patients, the
risk was in part attributed to an SNP located in the large first
intron of MAPT, which potentially modulated tau expression
by modifying an LBP-1c/LSF/CP2 binding site. This tran-
scription factor was shown to regulate the expression of genes
in other neurodegenerative disorders [124]. A two-staged
genome-wide association study in 2,165 PSP patients con-
firmed and extended these findings, and further implicated
STX6, EIF2AK3, and MOBP in PSP [64]. Together, these
genes suggested roles of vesicle-membrane fusion at the
Golgi–endosomal interface, the endoplasmic reticulum
unfolded protein response, and a myelin structure in PSP. The
role of these genes in other tauopathies remains to be
investigated.
Summary
FTLD is a clinically, neuropathologically and genetically
heterogeneous group of disorders with plenty of overlaps
between the neurodegenerative mechanism and the clinical
expression thereof. As many clinical syndromes belonging
to FTLD tend to overlap especially in advanced disease
stages, e.g. SD and bvFTD in the TDP-43 proteinopathies,
aFTLD-U and NIFID in the FUS proteinopathies, identi-
fying the symptomatology of the patient at an early stage of
the disease course is crucial. In that respect, concerted
evaluation of clinical and pathological parameters is
helpful to obtain a precise diagnosis. The general clinical
presentation of FTLD concurs with macroscopic charac-
teristics of brain atrophy including localization, symmetry
and degree of atrophy. The underlying neuropathological
abnormalities, i.e. the proteinopathies are closely linked
with the disease mechanism and are important diagnostic
markers. Detailed information on the underlying neuropa-
thology thus provides useful insights for early diagnosis,
disease course prognosis and patient counseling and treat-
ment that could not be obtained by clinical evaluation
alone. Imaging, biological and genetic biomarkers are
valuable parameters to assess the underlying pathological
characteristics of the disease. Further research is needed to
elicit additional biomarkers to extend the ability to char-
acterize neuropathological causes of disease and to further
specify clinicopathological correlations.
Despite immense progress in defining neuropatho-
logical abnormalities in FTLD diseases, not all FTLD
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proteinopathies are fully characterized yet. In the small
group of FTLD-UPS patients, the protein accumulating in
pathological aggregates remains to be identified. Similarly,
not all mutations underlying the proteinopathies have been
identified. Especially in the TDP-43 proteinopathies, sev-
eral yet unknown Mendelian and susceptibility genes are
expected to play a role. Specifically for FTLD-TDP type C,
no gene has yet been identified. This type of proteinopathy
is associated with clinical SD, in which family history was
reported to be the least prominent and future genome-wide
association studies may provide further insights in the
genetics of this disease.
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